Canaccord lowered the firm’s price target on Merit Medical (MMSI) to $90 from $99 and keeps a Buy rating on the shares. The fim updated its model to reflect the View Point Medical acquisition for $140M which expandis its oncology portfolio.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical acquires View Point to expand oncology portfolio
- Merit Medical acquires View Point Medical for $140M
- Merit Medical Systems: Leveraging Medtronic Partnership to Enter High-Growth Interventional Pain Market
- Medtronic, Merit Medical enter pact to offer new, FDA-cleared ViaVerte system
- Merit Medical launches Resilience TTS Esophageal Stent